Loading…
Reported covered position: Director, Regulatory and Reimbursement Affairs
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Promoting Integrity in Medicare Act of 2013
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93), misvalued codes, CMS billing practices, and appropriate test utilization; narrowing the in-office ancillary services to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, and H.R. 2914, the Promoting Integrity in Medicare Act of 2014.
Promoting Integrity in Medicare Act of 2013
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2014 · fourth_quarter · Q4
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93), misvalued codes, CMS billing practices, and appropriate test utilization; narrowing the in-office ancillary services to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, and H.R. 2914, the Promoting Integrity in Medicare Act of 2014.
Policies affecting reimbursement and regulation of clinical laboratories.
Source: Senate LDA
Reimbursement and coverage issues related to both the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014 (P.L. 113-93, misvalued codes, pricing for molecular diagnostic tests by CMS, billing practices, and appropriate test utilization. Issues related to the draft guidance released by FDA to regulate laboratory-developed tests (LDTs). Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Promoting Integrity in Medicare Act of 2013
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93), misvalued codes, CMS billing practices, and appropriate test utilization; narrowing the in-office ancillary services to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2014; 21st Century Cures Initiative; and the regulation and oversight of clinical laboratories.
Promoting Integrity in Medicare Act of 2013
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues related to both the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014 (P.L. 113-93, misvalued codes, pricing for molecular diagnostic tests by CMS, billing practices, and appropriate test utilization. Issues related to the draft guidance released by FDA to regulate laboratory-developed tests (LDTs). Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Promoting Integrity in Medicare Act of 2013
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014(P.L. 113-93), misvalued codes, and pricing for molecular diagnostic tests by CMS. Proposed FDA regulation of laboratory-developed tests. Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy services, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Promoting Integrity in Medicare Act of 2013
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014(P.L. 113-93), misvalued codes, and pricing for molecular diagnostic tests by CMS. Proposed FDA regulation of laboratory-developed tests. Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy services, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Promoting Integrity in Medicare Act of 2013
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014(P.L. 113-93), misvalued codes, and pricing for molecular diagnostic tests by CMS. Proposed FDA regulation of laboratory-developed tests. Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy services, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Promoting Integrity in Medicare Act of 2013
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014(P.L. 113-93), misvalued codes, and pricing for molecular diagnostic tests by CMS. Proposed FDA regulation of laboratory-developed tests. Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy services, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Promoting Integrity in Medicare Act of 2013
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93), misvalued codes, CMS billing practices, and appropriate test utilization; narrowing the in-office ancillary services to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2014; 21st Century Cures Initiative; and the regulation and oversight of clinical laboratories.
Promoting Integrity in Medicare Act of 2013
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues related to both the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014 (P.L. 113-93, misvalued codes, pricing for molecular diagnostic tests by CMS, billing practices, and appropriate test utilization. Issues related to the draft guidance released by FDA to regulate laboratory-developed tests (LDTs). Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Promoting Integrity in Medicare Act of 2013
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Reimbursement and coverage issues related to both the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014 (P.L. 113-93, misvalued codes, pricing for molecular diagnostic tests by CMS, billing practices, and appropriate test utilization. Issues related to the draft guidance released by FDA to regulate laboratory-developed tests (LDTs). Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Protecting Access to Medicare Act of 2014
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including H.R.4302, the Protecting Access to Medicare Act of 2014, pricing for molecular diagnostic tests, and other items in the Final FY2015 PFS Rule. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the federal self-referral law.
Protecting Access to Medicare Act of 2014
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including H.R.4302, the Protecting Access to Medicare Act of 2014, pricing for molecular diagnostic tests, and other items in the Final FY2015 PFS Rule. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the federal self-referral law. TRICARE rules affecting beneficiary access to clinical laboratory services.
Protecting Access to Medicare Act of 2014
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including H.R.4302, the Protecting Access to Medicare Act of 2014, pricing for molecular diagnostic tests, and other items in the Final FY2015 PFS Rule. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the federal self-referral law.
Protecting Access to Medicare Act of 2014
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including H.R.4302, the Protecting Access to Medicare Act of 2014, pricing for molecular diagnostic tests, and other items in the Final FY2015 PFS Rule. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the federal self-referral law.
A bill to extend the temporary suspension of duty on 1,3-Benzenedicarboxamide, N, N'-bis-(2,2,6,6-tetramethyl-4-piperidinyl)-.
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
TRICARE rules affecting beneficiary access to clinical laboratory services, especially molecular diagnostics. H.R. 4435, the Howard P. "Buck" McKeon National Defense Authorization Act for FY 2015. S. 2410, the Carl Levin National Defense Authorization Act for FY 2015.
A bill to extend the temporary suspension of duty on 1,3-Benzenedicarboxamide, N, N'-bis-(2,2,6,6-tetramethyl-4-piperidinyl)-.
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
TRICARE rules affecting beneficiary access to clinical laboratory services. H.R. 4435, the Howard P. "Buck" McKeon National Defense Authorization Act for FY 2015. S. 2410, the Carl Levin National Defense Authorization Act for FY 2015.
A bill to extend the temporary suspension of duty on 1,3-Benzenedicarboxamide, N, N'-bis-(2,2,6,6-tetramethyl-4-piperidinyl)-.
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
TRICARE rules affecting beneficiary access to clinical laboratory services, especially molecular diagnostics. H.R. 4435, the Howard P. "Buck" McKeon National Defense Authorization Act for FY 2015. S. 2410, the Carl Levin National Defense Authorization Act for FY 2015.
Economic Growth and Reducing Unemployment Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of the medical device tax to laboratory tests and the Clinical Laboratory Fee Schedule; the oversight of laboratory-developed tests, H.R. 3207, the Modernizing Laboratory Tests Standards for Patients Act of 2011; the Budget Control Act of 2011 (P.L. 112-225);in-office ancillary services exception to Stark law; H.R. 3060, the Middle Class Tax Relief and Job Creation Act of 2012 (P.L. 112-96).
Modernizing Laboratory Test Standards for Patients Act of 2011
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of medical device tax to clinical laboratories; in-office ancillary services exception to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards for Patients Act; H.R. 6118.S.3391, the Taking Essential Steps for Testing Act; the coding and pricing and placement of molecular pathology laboratory tests
Modernizing Laboratory Test Standards for Patients Act of 2011
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of the medical device tax to clinical laboratories; in office ancillary services exemption to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards Act for Patients Act; H.R. 6118/S. 3391, the Taking Essential Steps for Testing Act; the coding, pricing, and placement of molecular pathology laboratory tests; Medicare Clinical Laboratory Fee Schedule reimbursement levels; H.R. 8, the American Taxpayer Relief Act of 2012
Modernizing Laboratory Test Standards for Patients Act of 2011
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of medical device tax to laboratory tests and laboraty fee schedule; the oversight of laboratory-developed tests, HR 3207, the Modernizing Laboratory Test Standards for Patients Act; Budget Control Act of 2011(PL 112-225); in-office ancillary services exception to Stark law; HR 3630, the Middle Class Tax Relief and Job Creation Act of 2012 (PL 112-96)
Modernizing Laboratory Test Standards for Patients Act of 2011
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of the medical device tax to laboratory tests and the Clinical Laboratory Fee Schedule; the oversight of laboratory-developed tests, H.R. 3207, the Modernizing Laboratory Tests Standards for Patients Act of 2011; the Budget Control Act of 2011 (P.L. 112-225);in-office ancillary services exception to Stark law; H.R. 3060, the Middle Class Tax Relief and Job Creation Act of 2012 (P.L. 112-96).
Modernizing Laboratory Test Standards for Patients Act of 2011
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of medical device tax to laboratory tests and laboraty fee schedule cuts; the oversight of laboratory-developed tests, HR 3207, the Modernizing Laboratory Test Standards for Patients Act; Budget Control Act of 2011(PL 112-225); in-office ancillary services exception to Stark law; HR 5651, Food and Drug Administration Reform Act, S. 3187, Food and Drug Administration Safety and Innovation Act, HR 6118, the Taking Essential Steps for Testing Act
Modernizing Laboratory Test Standards for Patients Act of 2011
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of the medical device tax to clinical laboratories; in office ancillary services exemption to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards Act for Patients Act; H.R. 6118/S. 3391, the Taking Essential Steps for Testing Act; the coding, pricing, and placement of molecular pathology laboratory tests; Medicare Clinical Laboratory Fee Schedule reimbursement levels; H.R. 8, the American Taxpayer Relief Act of 2012
Modernizing Laboratory Test Standards for Patients Act of 2011
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of the medical device tax to clinical laboratories; in office ancillary services exemption to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards Act for Patients Act; H.R. 6118/S. 3391, the Taking Essential Steps for Testing Act; the coding, pricing, and placement of molecular pathology laboratory tests; Medicare Clinical Laboratory Fee Schedule reimbursement levels; H.R. 8, the American Taxpayer Relief Act of 2012
Modernizing Laboratory Test Standards for Patients Act of 2011
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of the medical device tax to clinical laboratories; in office ancillary services exemption to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards Act for Patients Act; H.R. 6118/S. 3391, the Taking Essential Steps for Testing Act; the coding, pricing, and placement of molecular pathology laboratory tests; Medicare Clinical Laboratory Fee Schedule reimbursement levels; H.R. 8, the American Taxpayer Relief Act of 2012
Food and Drug Administration Reform Act of 2012
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of medical device tax to laboratory tests and laboraty fee schedule cuts; the oversight of laboratory-developed tests, HR 3207, the Modernizing Laboratory Test Standards for Patients Act; Budget Control Act of 2011(PL 112-225); in-office ancillary services exception to Stark law; HR 5651, Food and Drug Administration Reform Act, S. 3187, Food and Drug Administration Safety and Innovation Act, HR 6118, the Taking Essential Steps for Testing Act
Taking Essential Steps for Testing Act of 2012
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of the medical device tax to clinical laboratories; in office ancillary services exemption to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards Act for Patients Act; H.R. 6118/S. 3391, the Taking Essential Steps for Testing Act; the coding, pricing, and placement of molecular pathology laboratory tests; Medicare Clinical Laboratory Fee Schedule reimbursement levels; H.R. 8, the American Taxpayer Relief Act of 2012
Taking Essential Steps for Testing Act of 2012
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of medical device tax to laboratory tests and laboraty fee schedule cuts; the oversight of laboratory-developed tests, HR 3207, the Modernizing Laboratory Test Standards for Patients Act; Budget Control Act of 2011(PL 112-225); in-office ancillary services exception to Stark law; HR 5651, Food and Drug Administration Reform Act, S. 3187, Food and Drug Administration Safety and Innovation Act, HR 6118, the Taking Essential Steps for Testing Act
Taking Essential Steps for Testing Act of 2012
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of the medical device tax to clinical laboratories; in office ancillary services exemption to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards Act for Patients Act; H.R. 6118/S. 3391, the Taking Essential Steps for Testing Act; the coding, pricing, and placement of molecular pathology laboratory tests; Medicare Clinical Laboratory Fee Schedule reimbursement levels; H.R. 8, the American Taxpayer Relief Act of 2012
Taking Essential Steps for Testing Act of 2012
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of the medical device tax to clinical laboratories; in office ancillary services exemption to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards Act for Patients Act; H.R. 6118/S. 3391, the Taking Essential Steps for Testing Act; the coding, pricing, and placement of molecular pathology laboratory tests; Medicare Clinical Laboratory Fee Schedule reimbursement levels; H.R. 8, the American Taxpayer Relief Act of 2012
Taking Essential Steps for Testing Act of 2012
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of the medical device tax to clinical laboratories; in office ancillary services exemption to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards Act for Patients Act; H.R. 6118/S. 3391, the Taking Essential Steps for Testing Act; the coding, pricing, and placement of molecular pathology laboratory tests; Medicare Clinical Laboratory Fee Schedule reimbursement levels; H.R. 8, the American Taxpayer Relief Act of 2012
Taking Essential Steps for Testing Act of 2012
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of medical device tax to clinical laboratories; in-office ancillary services exception to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards for Patients Act; H.R. 6118.S.3391, the Taking Essential Steps for Testing Act; the coding and pricing and placement of molecular pathology laboratory tests
American Taxpayer Relief Act of 2012
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of the medical device tax to clinical laboratories; in office ancillary services exemption to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards Act for Patients Act; H.R. 6118/S. 3391, the Taking Essential Steps for Testing Act; the coding, pricing, and placement of molecular pathology laboratory tests; Medicare Clinical Laboratory Fee Schedule reimbursement levels; H.R. 8, the American Taxpayer Relief Act of 2012
American Taxpayer Relief Act of 2012
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of the medical device tax to clinical laboratories; in office ancillary services exemption to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards Act for Patients Act; H.R. 6118/S. 3391, the Taking Essential Steps for Testing Act; the coding, pricing, and placement of molecular pathology laboratory tests; Medicare Clinical Laboratory Fee Schedule reimbursement levels; H.R. 8, the American Taxpayer Relief Act of 2012
American Taxpayer Relief Act of 2012
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of the medical device tax to clinical laboratories; in office ancillary services exemption to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards Act for Patients Act; H.R. 6118/S. 3391, the Taking Essential Steps for Testing Act; the coding, pricing, and placement of molecular pathology laboratory tests; Medicare Clinical Laboratory Fee Schedule reimbursement levels; H.R. 8, the American Taxpayer Relief Act of 2012
American Taxpayer Relief Act of 2012
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
Health reform law implementation issues including application of the medical device tax to clinical laboratories; in office ancillary services exemption to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards Act for Patients Act; H.R. 6118/S. 3391, the Taking Essential Steps for Testing Act; the coding, pricing, and placement of molecular pathology laboratory tests; Medicare Clinical Laboratory Fee Schedule reimbursement levels; H.R. 8, the American Taxpayer Relief Act of 2012
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93), misvalued codes, CMS billing practices, and appropriate test utilization; narrowing the in-office ancillary services to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2014; 21st Century Cures Initiative; and the regulation and oversight of clinical laboratories.
TRICARE rules affecting beneficiary access to clinical laboratory services, especially molecular diagnostics. H.R. 4435, the Howard P. "Buck" McKeon National Defense Authorization Act for FY 2015. S. 2410, the Carl Levin National Defense Authorization Act for FY 2015.
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93), misvalued codes, CMS billing practices, and appropriate test utilization; narrowing the in-office ancillary services to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2014; 21st Century Cures Initiative; and the regulation and oversight of clinical laboratories.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2014 · third_quarter · Q3
Reimbursement and coverage issues related to both the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014 (P.L. 113-93, misvalued codes, pricing for molecular diagnostic tests by CMS, billing practices, and appropriate test utilization. Issues related to the draft guidance released by FDA to regulate laboratory-developed tests (LDTs). Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
TRICARE rules affecting beneficiary access to clinical laboratory services, especially molecular diagnostics. H.R. 4435, the Howard P. "Buck" McKeon National Defense Authorization Act for FY 2015. S. 2410, the Carl Levin National Defense Authorization Act for FY 2015.
Reimbursement and coverage issues related to both the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014 (P.L. 113-93, misvalued codes, pricing for molecular diagnostic tests by CMS, billing practices, and appropriate test utilization. Issues related to the draft guidance released by FDA to regulate laboratory-developed tests (LDTs). Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Reimbursement and coverage issues related to both the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014 (P.L. 113-93, misvalued codes, pricing for molecular diagnostic tests by CMS, billing practices, and appropriate test utilization. Issues related to the draft guidance released by FDA to regulate laboratory-developed tests (LDTs). Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Reimbursement and coverage issues related to both the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014 (P.L. 113-93, misvalued codes, pricing for molecular diagnostic tests by CMS, billing practices, and appropriate test utilization. Issues related to the draft guidance released by FDA to regulate laboratory-developed tests (LDTs). Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2014 · second_quarter · Q2
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014(P.L. 113-93), misvalued codes, and pricing for molecular diagnostic tests by CMS. Proposed FDA regulation of laboratory-developed tests. Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy services, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014(P.L. 113-93), misvalued codes, and pricing for molecular diagnostic tests by CMS. Proposed FDA regulation of laboratory-developed tests. Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy services, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014(P.L. 113-93), misvalued codes, and pricing for molecular diagnostic tests by CMS. Proposed FDA regulation of laboratory-developed tests. Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy services, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act of 2014(P.L. 113-93), misvalued codes, and pricing for molecular diagnostic tests by CMS. Proposed FDA regulation of laboratory-developed tests. Narrowing the In-Office Ancillary Services Exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy services, H.R. 2914, the Promoting Integrity in Medicare Act of 2013. 21st Century Cures Initiative.
TRICARE rules affecting beneficiary access to clinical laboratory services. H.R. 4435, the Howard P. "Buck" McKeon National Defense Authorization Act for FY 2015. S. 2410, the Carl Levin National Defense Authorization Act for FY 2015.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2014 · first_quarter · Q1
TRICARE rules affecting beneficiary access to clinical laboratory services.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including H.R.4302, the Protecting Access to Medicare Act of 2014, pricing for molecular diagnostic tests, and other items in the Final FY2015 PFS Rule. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the federal self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including H.R.4302, the Protecting Access to Medicare Act of 2014, pricing for molecular diagnostic tests, and other items in the Final FY2015 PFS Rule. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the federal self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including H.R.4302, the Protecting Access to Medicare Act of 2014, pricing for molecular diagnostic tests, and other items in the Final FY2015 PFS Rule. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the federal self-referral law. TRICARE rules affecting beneficiary access to clinical laboratory services.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including H.R.4302, the Protecting Access to Medicare Act of 2014, pricing for molecular diagnostic tests, and other items in the Final FY2015 PFS Rule. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the federal self-referral law.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2013 · second_quarter · 2A
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), President of the U.S., SENATE
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2013 · fourth_quarter · Q4
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed and final regulatory reimbursement cuts in the CY 2014 PFS rule as well as potential legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
TRICARE coverage of molecular pathology tests.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed and final regulatory reimbursement cuts in the CY 2014 PFS rule as well as potential legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2013 · third_quarter · Q3
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbusement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory reimbursement cuts by CMS in the CY 2014 PFS rule as well as potential legislative reimbursement cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbusement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory reimbursement cuts by CMS in the CY 2014 PFS rule as well as potential legislative reimbursement cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2013 · second_quarter · Q2
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exeception to the Stark self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exeception to the Stark self-referral law.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2013 · first_quarter · Q1
Medicare Clinical Laboratory Fee Schedule reimbursement issues; regulation of laboratory-developed tests; closing the in-office ancillary services exemption to the Stark law; and health reform law implementation issues, including application of the medical device tax to clinical laboratories.
Medicare Clinical Laboratory Fee Schedule reimbursement issues; regulation of laboratory-developed tests; closing the in-office ancillary services exemption to the Stark law; and health reform law implementation issues, including application of the medical device tax to clinical laboratories.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2012 · first_quarter · 1A
Health reform law implementation issues including application of the medical device tax to laboratory tests and the Clinical Laboratory Fee Schedule; the oversight of laboratory-developed tests, H.R. 3207, the Modernizing Laboratory Tests Standards for Patients Act of 2011; the Budget Control Act of 2011 (P.L. 112-225);in-office ancillary services exception to Stark law; H.R. 3060, the Middle Class Tax Relief and Job Creation Act of 2012 (P.L. 112-96).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2012 · fourth_quarter · RA
Medicare reimbursement for clinical laboratory services; health care reform law implementation issues including application of the medical device tax to clinical laboratories; closing the in-office ancillary services exception to the Stark Law; the regulation of laboratory developed tests; the coding and pricing of molecular pathology laboratory tests; reimbursement and coding issues related to the Clinical Laboratory Fee Schedule; and reimbursement and coding issues related to the Physician Fee Schedule.
Medicare reimbursement for clinical laboratory services; health care reform law implementation issues including application of the medical device tax to clinical laboratories; closing the in-office ancillary services exception to the Stark Law; the regulation of laboratory developed tests; the coding and pricing of molecular pathology laboratory tests; reimbursement and coding issues related to the Clinical Laboratory Fee Schedule; and reimbursement and coding issues related to the Physician Fee Schedule.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2012 · fourth_quarter · 4A
Health reform law implementation issues including application of the medical device tax to clinical laboratories; in office ancillary services exemption to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards Act for Patients Act; H.R. 6118/S. 3391, the Taking Essential Steps for Testing Act; the coding, pricing, and placement of molecular pathology laboratory tests; Medicare Clinical Laboratory Fee Schedule reimbursement levels; H.R. 8, the American Taxpayer Relief Act of 2012
Health reform law implementation issues including application of the medical device tax to clinical laboratories; in office ancillary services exemption to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards Act for Patients Act; H.R. 6118/S. 3391, the Taking Essential Steps for Testing Act; the coding, pricing, and placement of molecular pathology laboratory tests; Medicare Clinical Laboratory Fee Schedule reimbursement levels; H.R. 8, the American Taxpayer Relief Act of 2012
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2012 · fourth_quarter · 4T
Health reform law implementation issues including application of the medical device tax to clinical laboratories; in office ancillary services exemption to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards Act for Patients Act; H.R. 6118/S. 3391, the Taking Essential Steps for Testing Act; the coding, pricing, and placement of molecular pathology laboratory tests; Medicare Clinical Laboratory Fee Schedule reimbursement levels; H.R. 8, the American Taxpayer Relief Act of 2012
Health reform law implementation issues including application of the medical device tax to clinical laboratories; in office ancillary services exemption to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards Act for Patients Act; H.R. 6118/S. 3391, the Taking Essential Steps for Testing Act; the coding, pricing, and placement of molecular pathology laboratory tests; Medicare Clinical Laboratory Fee Schedule reimbursement levels; H.R. 8, the American Taxpayer Relief Act of 2012
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2012 · third_quarter · Q3
Health reform law implementation issues including application of medical device tax to clinical laboratories; in-office ancillary services exception to the Stark law; H.R. 3207, the Modernizing Laboratory Test Standards for Patients Act; H.R. 6118.S.3391, the Taking Essential Steps for Testing Act; the coding and pricing and placement of molecular pathology laboratory tests
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2012 · second_quarter · Q2
Health reform law implementation issues including application of medical device tax to laboratory tests and laboraty fee schedule cuts; the oversight of laboratory-developed tests, HR 3207, the Modernizing Laboratory Test Standards for Patients Act; Budget Control Act of 2011(PL 112-225); in-office ancillary services exception to Stark law; HR 5651, Food and Drug Administration Reform Act, S. 3187, Food and Drug Administration Safety and Innovation Act, HR 6118, the Taking Essential Steps for Testing Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, White House Office
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2012 · first_quarter · Q1
Health reform law implementation issues including application of medical device tax to laboratory tests and laboraty fee schedule; the oversight of laboratory-developed tests, HR 3207, the Modernizing Laboratory Test Standards for Patients Act; Budget Control Act of 2011(PL 112-225); in-office ancillary services exception to Stark law; HR 3630, the Middle Class Tax Relief and Job Creation Act of 2012 (PL 112-96)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed and final regulatory reimbursement cuts in the CY 2014 PFS rule as well as potential legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed and final regulatory reimbursement cuts in the CY 2014 PFS rule as well as potential legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Defense, Dept of (DOD), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbusement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory reimbursement cuts by CMS in the CY 2014 PFS rule as well as potential legislative reimbursement cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbusement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory reimbursement cuts by CMS in the CY 2014 PFS rule as well as potential legislative reimbursement cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the Stark self-referral law.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE, White House Office
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exeception to the Stark self-referral law.
Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including gapfill pricing for molecular diagnostic tests and proposed regulatory and legislative cuts. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exeception to the Stark self-referral law.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), President of the U.S., SENATE
Medicare Clinical Laboratory Fee Schedule reimbursement issues; regulation of laboratory-developed tests; closing the in-office ancillary services exemption to the Stark law; and health reform law implementation issues, including application of the medical device tax to clinical laboratories.
Medicare Clinical Laboratory Fee Schedule reimbursement issues; regulation of laboratory-developed tests; closing the in-office ancillary services exemption to the Stark law; and health reform law implementation issues, including application of the medical device tax to clinical laboratories.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), President of the U.S., SENATE
Medicare reimbursement for clinical laboratory services; health care reform law implementation issues including application of the medical device tax to clinical laboratories; closing the in-office ancillary services exception to the Stark Law; the regulation of laboratory developed tests; the coding and pricing of molecular pathology laboratory tests; reimbursement and coding issues related to the Clinical Laboratory Fee Schedule; and reimbursement and coding issues related to the Physician Fee Schedule.
Medicare reimbursement for clinical laboratory services; health care reform law implementation issues including application of the medical device tax to clinical laboratories; closing the in-office ancillary services exception to the Stark Law; the regulation of laboratory developed tests; the coding and pricing of molecular pathology laboratory tests; reimbursement and coding issues related to the Clinical Laboratory Fee Schedule; and reimbursement and coding issues related to the Physician Fee Schedule.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), President of the U.S., SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), President of the U.S., SENATE